Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

F-calprotectin and blood markers correlate to Quality of Life in Pediatric Inflammatory Bowel Disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Serum Calprotectin in Adolescents with Inflammatory Bowel Disease - A Pilot Investigation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Bovine Colostrum For Preterm Infants in the First Days of Life: A Randomized Controlled Pilot Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Surgical Management of Crohn Disease in Children - Guidelines from the Paediatric IBD Porto Group of ESPGHAN

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effect of Probiotics on Diarrhea in Children With Severe Acute Malnutrition: A Randomized Controlled Study in Uganda

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative colitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Coping Among Parents of Teens With Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Editorial: suicide and IBD-a call to action. Authors' reply

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: Our aim was to investigate predictors of Health Related Quality of Life (HRQoL) with respect to changes in disease parameters over time in children with Inflammatory Bowel Disease (IBD).

METHODS: This was a prospective longitudinal study examining the association between HRQoL (IMPACT III) and symptom scores (PCDAI, abbrPUCAI), fecal calprotectin (FC) measures and blood analyses (C-reactive protein [CRP], erythrocyte sedimentation-rate [ESR], orosomucoid [ORM], albumin [ALB], hemoglobin [HB] and vitamin-D [VIT-D]) in a cohort of 10-17 years old IBD patients. Data were collected prospectively at three-month intervals during a two-year period. Associations were analyzed using linear Mixed Effect Models. Patients were divided into two groups which received Non-biological oral treatment or Biological parenteral treatment.

RESULTS: From 79 patients (39 Crohn Disease [CD]/ 40 ulcerative colitis [UC]), representing a total of 43,132 days of observation, 572 IMPACT measurements were paired with variables. A decrease in the IMPACT III score was significantly associated with increased UC-symptom score in the Biological group (P = 0.005), and a similar inverse tendency was found in the Non-biological group and for CD-symptoms in both groups. We found in both treatment groups overall a significant (P < 0.05) inverse association between the IMPACT III and the levels of FC, ESR and ORM whereas ALB, HB and VIT-D were directly significant associated.

CONCLUSIONS: The IMPACT score, already known to correlate with disease activity, has now been shown to be associated with disease markers in feces and blood. This emphasizes that objective markers of disease activity indirectly can predict the patient's HRQoL.

OriginalsprogEngelsk
TidsskriftJournal of Pediatric Gastroenterology and Nutrition
Vol/bind65
Udgave nummer5
Sider (fra-til)539-545
ISSN0277-2116
DOI
StatusUdgivet - nov. 2017

ID: 49918837